Harbin Pharmaceutical Group Co (SHSE:600664) Days Payable: 118.98 (As of Mar. 2026) — Near Median


SHSE:600664 Harbin Pharmaceutical Group Co Ltd SHSE:600664
73 GF Score
Price ¥3.37
GF Value ¥3.51
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Harbin Pharmaceutical Group Co Days Payable?

Harbin Pharmaceutical Group Co SHSE:600664 +10.13% 73 Days Payable is 118.98 as of Mar. 2026, which is 8% below its 10-year median of 129.64. GuruFocus rates SHSE:600664 with a GF Score™ of 73/100 and a GF Value™ of ¥3.51 (Fairly Valued). The stock has 2 warning signs investors should review. Among 927 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks better than 66.67% on this metric.

Harbin Pharmaceutical Group Co's average Accounts Payable for the three months ended in Mar. 2026 was ¥4,132 Mil. Harbin Pharmaceutical Group Co's Cost of Goods Sold for the three months ended in Mar. 2026 was ¥3,169 Mil. Hence, Harbin Pharmaceutical Group Co's Days Payable for the three months ended in Mar. 2026 was 118.98.

The historical rank and industry rank for Harbin Pharmaceutical Group Co's Days Payable or its related term are showing as below:

SHSE:600664' s Days Payable Range Over the Past 10 Years
Min: 119.38   Med: 129.64   Max: 159.79
Current: 122.46

During the past 13 years, Harbin Pharmaceutical Group Co's highest Days Payable was 159.79. The lowest was 119.38. And the median was 129.64.

SHSE:600664's Days Payable is ranked better than
66.67% of 927 companies
in the Drug Manufacturers industry
Industry Median: 90.38 vs SHSE:600664: 122.46

Harbin Pharmaceutical Group Co's Days Payable declined from Mar. 2025 (119.11) to Mar. 2026 (118.98). It may suggest that Harbin Pharmaceutical Group Co accelerated paying its suppliers.


Harbin Pharmaceutical Group Co Days Payable Historical Data

* Premium members only.

The historical data trend for Harbin Pharmaceutical Group Co's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harbin Pharmaceutical Group Co Days Payable Chart

Harbin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 133.62 122.67 119.38 125.62 124.67

Harbin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.11 124.30 119.76 124.29 118.98

SHSE:600664 vs ZTS, UTHR: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Pharmaceutical Group Co Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Days Payable distribution charts can be found below:

* The bar in red indicates where Harbin Pharmaceutical Group Co's Days Payable falls into.


SHSE:600664
73GF Score
Harbin Pharmaceutical Group Co Ltd SHSE:600664
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harbin Pharmaceutical Group Co Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Harbin Pharmaceutical Group Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (4039.237 + 4032.451) / 2 ) / 11815.835*365
=4035.844 / 11815.835*365
=124.67

Harbin Pharmaceutical Group Co's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (4032.451 + 4230.64) / 2 ) / 3168.65*365 / 4
=4131.5455 / 3168.65*365 / 4
=118.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 118.98 mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Days Payable of 118.98 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harbin Pharmaceutical Group Co and its competitors. This is near median its historical median of 129.64. Over the past decade, Harbin Pharmaceutical Group Co's Days Payable has ranged from 119.38 to 159.79. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #309 out of 927 companies in the Drug Manufacturers industry, placing it in the top 33.3%.
Is Harbin Pharmaceutical Group Co's Days Payable too high?
Harbin Pharmaceutical Group Co's current Days Payable of 118.98 is near median its 10-year median of 129.64. Over the past 10 years, this metric has ranged from a low of 119.38 to a high of 159.79. The Drug Manufacturers industry median Days Payable is 90.38. Harbin Pharmaceutical Group Co's value of 118.98 is 31.6% above this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #309 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #309 out of 927 companies for Days Payable. This puts Harbin Pharmaceutical Group Co in the upper half of its industry. The industry median Days Payable is 90.38. Harbin Pharmaceutical Group Co's value of 118.98 is 31.6% above this benchmark. Historically, Harbin Pharmaceutical Group Co's own Days Payable has ranged from 119.38 to 159.79 over the past decade. While the company's 10-year median is 129.64 vs. the industry median of 90.38, Harbin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current Days Payable of 118.98 is 31.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current Days Payable is 118.98, which is near median its own 10-year median of 129.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Fairly Valued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥3.37 — trading 4% below its estimated fair value. The current Days Payable is 118.98, which is near median its 10-year median of 129.64 and 31.6% above the Drug Manufacturers industry median of 90.38. Harbin Pharmaceutical Group Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Days Payable is 118.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?

Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥3.37 is trading 4% below its estimated GF Value™ of ¥3.51. GuruFocus considers Harbin Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600664:

  • Days Payable: 118.98 (near median its 10-year median of 129.64)
  • GF Value™: ¥3.51 vs. price of ¥3.37 (4% below fair value)
  • GF Score™: 73/100 with 2 warning signs
  • Industry Position: 31.6% above the Drug Manufacturers median (#309 of 927)

No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harbin Pharmaceutical Group Co Business Description

Address Xi\'an Street West, People \'s Development Zone Baoan Road South, Heilongjiang Province, Harbin, CHN, 150018
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
73GF Score

Get the complete analysis for SHSE:600664

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥3.37
Price
¥3.51
GF Value